Atara Biotherapeutics is a leading "Off-the-Shelf" T-cell immunotherapy company developing products for patients with cancer and Multiple Sclerosis (MS). The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA.
Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) and other EBV positive solid tumors is expected to enter Phase 3 clinical studies in 2017. Atara's next generation T-cell immunotherapy for autoimmune disease is an EBV-specific CTL product candidate, or ATA188, that selectively targets specific antigens of EBV believed to be important for the potential treatment of MS.
Subscribe now to stay connected on the latest T-cell immunotherapy development, business and financial updates from Atara.
Day Low: 14.45
Events & Presentations
Atara Biotherapeutics Corporate Presentation